Trillium Therapeutics Inc. (TRIL) Stock: Is This Biotech Stock Worth Your Attention?


Trillium Therapeutics Inc. (TRIL) is gaining in the market in today’s trading session. The company, one that is focused in the biotech sector, is currently priced at $0.73 after climbing 6.09% so far in today’s session. When it comes to biotech stocks, there are several aspects that have the potential to cause movement in the market. One of the most common is news. Here are the recent headlines centered around TRIL:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-11-19 06:10PM Trillium: 4Q Earnings Snapshot
05:09PM Trillium Therapeutics Reports Annual Financial and Operating Results
Mar-08-19 06:37PM Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
Feb-22-19 09:00AM Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
Feb-21-19 04:00PM Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

Nonetheless, any time investors are making a decision with regard to investing, investors should look at much more than news, this is especially the case in the highly speculative biotechnology sector. Here’s what’s happing when it comes to Trillium Therapeutics Inc..

Returns That TRIL Investors Have Seen

Although a single session gain, like what we’re seeing from Trillium Therapeutics Inc. might lead to excitement in some investors, that by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally a good idea to look at trends just a single trading day. In the case of TRIL, here are the returns on investment that investors have seen:

  • Past 5 Sessions – Throughout the last 7 days, TRIL has seen a change in value in the amount of 2.50%.
  • Monthly – The ROI from Trillium Therapeutics Inc. over the past 30 days has been -41.40%.
  • Past Three Months – In the past quarter, the stock has generated a return that works out to -64.72%
  • Past 6 Months – In the past six months, we have seen a performance of -87.79% from the company.
  • Year To Date – Since the the first trading session of this year TRIL has resulted in a ROI of -57.50%.
  • Annually – Finally, throughout the past full year, investors have seen performance in the amount of -90.50% from TRIL. Over this period of time, the stock has sold at a high price of -91.35% and a low of 11.80%.

Notable Ratios

Looking at various ratios associated with a company can give prospective investors a view of how risky and/or rewarding a an investment option may be. Below are a few of the important ratios to think about when looking at TRIL.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors are expecting that the value of the stock is going to tumble. Across the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we also see quite a few short squeezes in the space. Nonetheless, in regard to Trillium Therapeutics Inc., it’s short ratio amounts to 0.92.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay its debts when they come due using current assets or quick assets. In the biotechnology sector, several companies are heavily reliant on continued support from investors, the current and quick ratios can be bad. Nonetheless, quite a few gems in the biotechnology industry do have great current and quick ratios. When it comes to TRIL, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. as it relates to Trillium Therapeutics Inc., that ratio equates to 0.09.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotechnology sector, this is a very important ratio to look into. In this case, the cash to share value works out to 0.

How Analysts Feel About Trillium Therapeutics Inc.

Although it’s not a good idea to unknowingly follow the opinions of analysts, it is a good idea to use their opinions to validate your own thoughts before making investment decisions in the biotechnology sector. Below are|Here are} the most recent moves that we’ve seen from analysts with regard to TRIL.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-13-18 Resumed Leerink Partners Mkt Perform $7
Jul-17-17 Initiated H.C. Wainwright Buy $7
Aug-03-16 Initiated Ladenburg Thalmann Buy $18
May-15-15 Initiated Oppenheimer Outperform $32
Apr-27-15 Initiated Leerink Partners Outperform $29

Is Big Money Interested In Trillium Therapeutics Inc.

An interesting fact that I’ve come to understand in my short time on Earth has been that smart money tends to follow the moves made by big money. In other words, investors that are trying to play it relatively safe will pay close attention to moves made by institutional investors as well as insiders of the company. With that said, what does the big money picture look like when it comes to TRIL? Here’s the data:

Institutions own 58.81% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0.37% percent of TRIL shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Investors and traders tend to be interested in the counts of shares both available and outstanding. In regard to Trillium Therapeutics Inc., currently there are 14.69M with a float of 10.23M. These data mean that out of the total of 14.69M shares of TRIL currently in existence today, 10.23M are able to be traded in the public space.

It’s also important to dig into the short percent. After all, if a large portion of the float is shorted, the overall feeling among traders is that the company is headed for a deep dive. When it comes to TRIL, the percentage of the float that is currently being sold short is 3.60%. Most traders believe that a concerning short percent of the float would be considered to be anything over 40%. Nonetheless, I’ve seen that any short percent of the float over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from TRIL in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands, analysts are expecting that TRIL will report EPS coming to a total of -2.92, with -0.90 to be reported in the earnings announcement for the current quarter. Although this data isn’t tide to earnings, since we are talking about Wall St. analysts, TRIL is currently rated a 1.50 on a scale from 1 to 5 where 1 is the worst average Wall Street analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past 5 years, Trillium Therapeutics Inc. has generated a change in sales volume that comes to a total of 0. Earnings per diluted share over the period have seen a change of 0.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally referred to as in the world of humans, TRIL has generated a change in earnings that amounts to 0. TRIL has also experienced movement with regard to sales that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here